NTHI
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- NeOnc Technologies announces an FDA End-of-Phase 1 meeting for NEO212Sep 28, 2026
- NeOnc Technology advances a new nasal delivery approach for treating brain cancerSep 21, 2026
- NeOnc Technologies reported positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade gliomaAug 12, 2026
- NeOnc Technologies secured UAE IND approval for NEO212 after completing Phase 1, advancing toward global Phase 2 developmentJun 17, 2026
- NeOnc Technologies completed enrollment in pivotal NEO100 Phase 2a trial for IDH-1 mutant recurrent high-grade glioma and expects interim data readout in six months (Q2 2026)Nov 14, 2025